Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec 2Q

Growth in the quarter was driven by Tysabri sales, up 27% to $188 million, and Avonex sales, up 12% to $591 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 2Q

2Q Revenues: $1.1 billion (+10%)

2Q Earnings: $144.9 million (-30%)

YTD Revenues: $2.1 billion (+11%)

YTD Earnings: $391.5 million (+5%)

Comments: Growth in the quarter was driven by Tysabri sales, up 27% to $188 million, and Avonex sales, up 12% to $591 million. Revenues include $276 million from Biogen’s joint business arrangement with Genentech for the co-promotion of Rituxan in the U.S. and a payment of $110 million related to the collaboration and license agreement with Acorda Therapeutics. R&D expenses in the quarter were up 65% to $416.5 million. Royalties were $25 million in the quarter compared to $28 million in 2Q08.

Sign up today for Contracting & Outsourcing 2009!
stagging_cp.rodpub.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters